- cafead   Jan 11, 2022 at 11:32: AM
via Andrew Obenshain officially took over as bluebird bio’s CEO when the company split into two back in November. But there’s one item from his prior desk that's still on his mind: the removal of Zynteglo from the European market.
article source
article source